Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Lin CC, et al. Among authors: rha sy. Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16. Cancer Chemother Pharmacol. 2009. PMID: 19449006 Clinical Trial.
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. de Bono JS, et al. Among authors: rha sy. Ann Oncol. 2004 Dec;15(12):1825-33. doi: 10.1093/annonc/mdh472. Ann Oncol. 2004. PMID: 15550589 Free article. Clinical Trial.
Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution.
Ma H, Srivastava S, Ho SWT, Xu C, Lian BSX, Ong X, Tay ST, Sheng T, Lum HYJ, Aishah Binte Abdul Ghani S, Chu Y, Huang KK, Goh YT, Lee M, Hagihara T, Shi Ya Ng C, Tan ALK, Zhang Y, Ding Z, Zhu F, Ng MSW, Joseph CRC, Chen H, Li Z, Zhao JJ, Rha SY, Teh M, Yeong J, Yong WP, So JB, Sundar R, Tan P. Ma H, et al. Among authors: rha sy. Cancer Discov. 2025 Jan 9. doi: 10.1158/2159-8290.CD-24-0605. Online ahead of print. Cancer Discov. 2025. PMID: 39774838
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK. Motzer RJ, et al. Among authors: rha sy. Ann Oncol. 2024 Dec 11:S0923-7534(24)04978-0. doi: 10.1016/j.annonc.2024.12.003. Online ahead of print. Ann Oncol. 2024. PMID: 39672382 Free article.
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial.
Lee DK, Lee CK, Kim HS, Sym SJ, Zang DY, Kim KH, Lim JH, Kim HS, Lee KH, Gee HY, Rha SY, Kim H, Jung M. Lee DK, et al. Among authors: rha sy. Cancer Res Treat. 2024 Nov 12. doi: 10.4143/crt.2024.705. Online ahead of print. Cancer Res Treat. 2024. PMID: 39529388 Free article.
518 results